Dr. Mohamed Rahmani is an accomplished scientist with extensive expertise in the field of cancer biology and signaling. He obtained his PhD from Paris 7 University in 1999 and subsequently completed three years of postdoctoral training at Virginia Commonwealth University and the Massey Cancer Center, Richmond Virginia. He was promoted to instructor (2003), assistant professor (2005), and associate professor (2010). Dr. Rahmani moved to the University of Sharjah and Sharjah Institute for Medical Research in 2017 where he developed and led the Gene Editing and Therapy research group for four years prior to joining Khalifa University in 2021.
His primary research areas include identification of cancer resistance to therapies using genome-wide CRISPR/Cas9-mediated loss-of-function screen, and developing novel therapeutic approaches. Dr. Rahmani’s work has consistently been published in leading biomedical journals, and has continuously been funded by highly competitive grants including RO1 and Specialized Programs of Research Excellence (SPOREs) NIH grants, V-Foundation, and leukemia & lymphoma society. Dr. Rahmani also secured substantial funding from local and national institutions during his tenure at the university of Sharjah.
He has been serving as associate editor and member of editorial board in multiple biomedical Journals and reviewing manuscripts for many well-respected Journals including Cancer Research Communications, Cancer research, Clinical Cancer Research, Blood, Oncogene among others.
